Omitting systematic biopsy in men with elevated prostate-specific antigen (PSA) levels and negative MRI results, and performing only targeted biopsy of MRI-positive lesions, eliminated more than half ...
Omitting biopsy in patients with a negative prostate MRI more than halves the diagnoses of clinically insignificant prostate cancer. Detection of clinically insignificant ISUP grade group 1 prostate ...
Biparametric MRI, which omits the dynamic contrast enhancement sequence, can detect clinically significant prostate cancer as well as multiparametric MRI. Biparametric MRI performs as well as ...
Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...
MARKHAM, Ontario--(BUSINESS WIRE)--Exact Imaging today announced results from its OPTIMUM clinical trial demonstrating the non-inferiority of its ExactVu™ micro-ultrasound platform to MRI ...
Koelis, SAS (“Koelis” or the “Company”, a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...
Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...
Dec. 15, 2025 — For decades, when tests suggested that a man might have prostate cancer, the next step was usually a biopsy. The procedure, where a doctor uses a thin needle to collect prostate ...
The result is Ezra (Hebrew for “help”), the full-body MRI scanning company Gal founded in 2018. In 2025, it was acquired by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback